June 2026

Ind-Swift Group, founded in 1986 and headquartered in Chandigarh, India, is a globally trusted pharmaceutical company recognized for its innovation, quality, and commitment to healthcare excellence. With a legacy built on scientific advancement and ethical practices, we have emerged as a powerful force in both Domestic and Export pharmaceutical markets.

Gilead Sciences has announced positive results from its Phase 3 IDEAL trial evaluating Livdelzi (seladelpar)in adults with primary biliary cholangitis (PBC), a rare chronic autoimmune liver disease. The study met its primary endpoint, demonstrating statistically significant improvement in a composite measure of alkaline phosphatase (ALP) normalization compared with placebo.

The Serum Institute of India (SII) has joined hands with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo strain of Ebola virus, a deadly pathogen currently driving outbreaks in the Democratic Republic of Congo (DRC) and Uganda. CEPI has committed up to 8.6 million USD to support the vaccine's advancement toward clinical testing.

Prescribing antibiotics for common sore throats may have only a minimal impact on preventing serious streptococcal infections, according to new research from the University of Gothenburg. The findings challenge a widely debated rationale for antibiotic use and highlight the importance of recognizing early signs of severe illness instead.